FDA: PGx considerations for Codeine use in Kids

The FDA today released a warning about the use of codeine, following four cases of overdose in children who exhibited evidence of being ultra-rapid metabolizers. An estimated 1-28% of individuals have the genetic variation that makes them ultra-rapid metabolizers of this drug. Pharmacogenomic testing is required to definitively determine an individual’s risk.

FDA is currently reviewing these cases and other information, and will update the public, as appropriate.

Click here to read the full release on the FDA website.

Click here for more information on Pharmacogenomics.